Search results: (10000)
News Longer survival without liver transplant in patients with PBC treated with OCA?
Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
News Acquired Hemophilia A Newly Diagnosed in an Elderly Patient − A Case Report
At the XXVIIIth Pařízek Days held in Ostrava, a case of acquired hemophilia A, recently addressed at this institution, was presented in the afternoon session on March 17, 2022, by Assoc. Prof. Petr Dulíček, MD, PhD., from the 4th Department of Internal Medicine, Charles University Faculty of Medicine and University Hospital in Hradec Králové.
News What situations can arise in PBC treatment with obeticholic acid? Answers provided by case studies from real practice at CKTCH
The Hradec Gastroenterology Days 2023 were traditionally held in March at the Educational Center of the Faculty of Medicine, Charles University, in the area of University Hospital Hradec Králové. The expert program included a lecture by MUDr. Libuše Husová, Ph.D., from the Cardio-surgical and Transplant Surgery Center Brno (CKTCH), who highlighted various situations that can arise during the treatment of primary biliary cholangitis (PBC) with three case studies.
News Experiences with treating PBC with obeticholic acid in Brno's CKTCH
MUDr. Libuše Husová, Ph.D., shared the current insights from the therapy of patients with primary biliary cholangitis (PBC) using obeticholic acid (OCA) gained at the Center for Cardiovascular and Transplantation Surgery in Brno (CKTCH) during the XLVIII May Hepatology Days.
News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?
In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature – this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.
News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children – Results of the TERIKIDS Study
Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.
News Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease
Albuminuria in patients with type 2 diabetes is associated with a higher risk of cardiovascular (CV) events and higher mortality. However, this association has not been thoroughly investigated in diabetics without evident atherosclerotic disease. A study with a large cohort of Danish patients helped fill in the missing data.
News Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
Brazilian authors published a review of available information on the mechanism of action of metamizole, its impact on gastrointestinal tract motility, its effect on the gastric mucosa, and its antispasmodic effects.
News Current View on Prophylactic Negative Pressure Wound Therapy in Practice from Surgeons' Perspective
The journal Updates in Surgery recently published the results of a survey on prophylactic negative-pressure wound therapy (pNPWT) conducted among Swiss surgeons. The survey results show how often this therapy is used, in what situations it is typically applied, and what could make negative-pressure wound therapy more attractive in the future.
News Does Tofacitinib Improve Comorbid Depressive and/or Anxiety Symptoms in Patients with Rheumatoid Arthritis?
Depression and anxiety disorders are commonly observed in patients with rheumatoid arthritis and can lead to a reduction in quality of life, functional capacity, and, last but not least, to a lower therapeutic response. Therefore, the study presented below examined the prevalence of depressive and generalized anxiety disorders in clinical trials using tofacitinib and the effectiveness of tofacitinib according to baseline values of depression and anxiety.
News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?
In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.
News Therapy with Cyclosporine in the Context of the Coronavirus Pandemic
The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises concerns about possible risks associated with immunosuppressive treatment of autoimmune diseases. Specifically, does the use of cyclosporine increase the risk of infection, or does it act protectively?
News Efficacy of Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Syndrome – Results of a Meta-Analysis
Dry eye syndrome affects 5–30% of individuals over the age of 50. The beneficial effect of hyaluronic acid on the symptoms of this condition has been well described in both preclinical and clinical studies, and it has been shown that its topical application increases the secretion of water and mucin on the surface of the eye. The meta-analysis presented below focused on the efficacy of eye drops containing hyaluronic acid in the treatment of dry eye syndrome.
News Frequency of Mutations in Genes Predisposing to Ovarian Cancer in the Czech Population
The authors of a Czech study evaluating the occurrence of mutations in tumor-predisposing genes for ovarian cancer hypothesized that if their occurrence in patients with this diagnosis was significant, identifying carriers of these mutations could help reduce the prevalence and mortality of this disease given the absence of other screening tools.
News How to Dose Beta-Blockers After Myocardial Infarction?
In patients after myocardial infarction (MI), there is a frequent administration of too low doses of beta-blockers (BB) and rare upward titration of their dose after discharge from the hospital. The SWEDEHEART study investigated to what extent the BB dose actually affects 5-year cardiovascular (CV) outcomes, and data from the American registry allowed a focus on mortality after MI depending on BB dosing.
News Is long-term treatment with ixekizumab sufficiently safe?
Psoriasis is a chronic inflammatory disease whose manifestations require long-term treatment. A poster presented at last year's European Academy of Dermatology and Venereology (EADV) congress summarizes ixekizumab safety data from monitoring lasting up to 5 years, based on nearly 18,000 patient-years (PY) in the treatment of this disease.
News Direct Oral Anticoagulants and Their Reversal Agents – Current Options
In the last 10 years, the options for anticoagulant therapy have expanded with the introduction of direct oral anticoagulants (DOACs). It appears that DOACs may soon replace warfarin in the first line of prevention of venous thromboembolism, not only due to their clinical advantages but also thanks to newly available reversal agents that can be administered in case of major bleeding in patients taking DOACs. A recently published review article summarizes the current situation in this area.
News Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in which the authors thoroughly examined current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction of the left ventricle (HFpEF). Recent studies in this heterogeneous disease suggest the importance of carefully determining the HFpEF phenotype in a given patient based on pathophysiology, which enables better individualization of treatment. The authors also reflect on the success of gliflozins in treating HFpEF and how HFpEF pharmacotherapy can be further improved.
News Therapy of Chronic Leg Ulcers According to Evidence-Based Medicine
Chronic ulcers on the lower extremities are defined as trophic defects that show no signs of healing after 3 months of appropriate treatment or are not healed even after 12 months of treatment. Their incidence and prevalence are continuously increasing, and they currently represent not only a serious medical problem but also a socioeconomic issue. An overview article published by German physicians focuses on summarizing the therapy of leg ulcers according to the principles of evidence-based medicine.
News Drops with Liposomal Ozonized Oil Reduce Ocular Microbial Burden Before Cataract Surgery
The periocular zone and conjunctiva are characterized by high microbial activity. Therefore, it is important to reduce this bacterial burden as part of preoperative prophylaxis before surgery to minimize the risk of infection. The aim of the study presented below, conducted in 20 Italian centers, was to evaluate the antimicrobial efficacy of a new ocular solution in patients undergoing cataract surgery.
News Fixed combinations of Enerzair® and Atecura® may improve asthma treatment
The newly approved fixed triple combination Enerzair® and the fixed dual combination Atectura® have demonstrated improvements in lung function and a reduction in exacerbations in previously uncontrolled asthma patients. Administering once daily using the Breezhaler® inhaler along with the possibility of connecting a digital aid aims, among other things, to facilitate usage and proper adherence to the treatment.
News Current News from ECCO 2023: Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice
At the 18th ECCO Congress, held in March 2023 in Copenhagen, results from a Spanish real-world study were presented. This study evaluated the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC), including the impact of this drug on extraintestinal manifestations of the disease and immune-mediated diseases.
News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis
What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC).
.
News OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?
How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.